Healthcare Worker Study Cohort to Determine the Level and Durability of Cellular and Humoral Immune Responses after Two Doses of SARS-CoV-2 Vaccination

Author:

Dentone Chiara,Fenoglio DanielaORCID,Ponzano Marta,Cerchiaro Matteo,Altosole TizianaORCID,Franciotta Diego,Portunato Federica,Mikulska MalgorzataORCID,Taramasso LuciaORCID,Magnasco LauraORCID,Uras Chiara,Magne Federica,Ferrera FrancescaORCID,Scavone Graziana,Signori Alessio,Vena Antonio,Visconti ValeriaORCID,Filaci GilbertoORCID,Sette AlessandroORCID,Grifoni AlbaORCID,Di Biagio AntonioORCID,Bassetti Matteo

Abstract

We prospectively studied immunological response against SARS-CoV-2 after vaccination among healthcare workers without (group A) and with previous infection (group B). The analyses were collected at T0 (before the BNT162b2), T1 (before the second dose), T2 and T6 (1 and 6 months after the second dose). For cellular immune response, the activation-induced cell marker assay was performed with CD4 and CD8 Spike peptide megapools expressed as Stimulation Index. For humoral immune response, we determined antibodies to Spike-1 and nucleocapsid protein. The linear mixed model compared specific times to T0. The CD4+ Spike response overall rate of change was significant at T1 (p = 0.038) and at T2 (p < 0.001), while decreasing at T6. For CD8+ Spike reactivity, the interaction between the time and group was significant (p = 0.0265), and the p value for group comparison was significant at the baseline (p = 0.0030) with higher SI in previously infected subjects. Overall, the anti-S Abs significantly increased from T1 to T6 compared to T0. The group B at T6 retained high anti-S titer (p < 0.001). At T6, in both groups we found a persistent humoral response and a high CD4+ T cell response able to cross recognize SARS-COV-2 variants including epsilon, even if not a circulating virus at that time.

Funder

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference43 articles.

1. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose;Reynolds;Science,2021

2. Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination;Painter;Immunity,2021

3. Adaptive immunity to SARS-CoV-2 and COVID-19;Sette;Cell,2021

4. The T cell immune response against SARS-CoV-2;Moss;Nat. Immunol.,2022

5. Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine;Oberhardt;Nature,2021

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3